{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:23:38Z","timestamp":1795235018123,"version":"4.10.3"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.phrs.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:41:44Z","timestamp":1395448904000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":631,"special_numbering":"C","title":["The pharmacology of statins"],"prefix":"10.1016","volume":"88","author":[{"given":"Cesare R.","family":"Sirtori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.03.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2004.08.007","article-title":"A tribute to Akira Endo, discoverer of a penicillin for cholesterol","volume":"5","author":"Brown","year":"2004","journal-title":"Ather Suppl"},{"key":"10.1016\/j.phrs.2014.03.002_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-5793(76)80996-9","article-title":"Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ML-236a and ML-236b fungal metabolites, having hypocholesterolemic activity","volume":"72","author":"Endo","year":"1976","journal-title":"FEBS Lett"},{"key":"10.1016\/j.phrs.2014.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","article-title":"Ml-236a, ML-236b, and ML-236c, new inhibitors of cholesterogenesis produced by penicillium citrinium","volume":"29","author":"Endo","year":"1976","journal-title":"J. Antibiot"},{"key":"10.1016\/j.phrs.2014.03.002_bib0020","first-page":"70","article-title":"Inhibition of in vitro cholesterol synthesis by fatty acids","volume":"486","author":"Kuroda","year":"1976","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2014.03.002_bib0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0021-9150(80)90185-9","article-title":"The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-a reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks","volume":"35","author":"Fears","year":"1980","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0030","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0021-9258(17)38120-6","article-title":"Induction of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in human fibroblasts incubated with compactin (ml-236b), a competitive inhibitor of the reductase","volume":"253","author":"Brown","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.03.002_bib0035","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1210\/endo-104-3-610","article-title":"Low density lipoprotein receptors in bovine adrenal cortex. II. Low density lipoprotein binding to membranes prepared from fresh tissue","volume":"104","author":"Kovanen","year":"1979","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2014.03.002_bib0040","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1073\/pnas.80.13.4124","article-title":"Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes","volume":"80","author":"Bilheimer","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.03.002_bib0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3476(88)80289-0","article-title":"Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover","volume":"113","author":"Uauy","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.phrs.2014.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1073\/pnas.78.2.1194","article-title":"Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog","volume":"78","author":"Kovanen","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2014.03.002_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0021-9150(80)90124-0","article-title":"Therapeutic effects of ML-236b in primary hypercholesterolemia","volume":"35","author":"Yamamoto","year":"1980","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1432-1033.1979.tb13177.x","article-title":"Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl-coenzyme-a reductase using two specific inhibitors","volume":"98","author":"Tanzawa","year":"1979","journal-title":"Eur J Biochem\/FEBS"},{"key":"10.1016\/j.phrs.2014.03.002_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0163-7258(85)90025-7","article-title":"Drugs inhibiting HMG-CoA reductase","volume":"31","author":"Endo","year":"1985","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0070","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1043-6618(05)80047-7","article-title":"Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors","volume":"22","author":"Sirtori","year":"1990","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0075","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-291X(89)92773-3","article-title":"Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo","volume":"158","author":"Germershausen","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2014.03.002_bib0080","first-page":"1383","article-title":"Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0163-7258(93)90031-8","article-title":"Tissue selectivity of hydroxymethylglutaryl coenzyme a (HMG-CoA) reductase inhibitors","volume":"60","author":"Sirtori","year":"1993","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2013 the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0095","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1001\/archinte.161.21.2630","article-title":"Case reports of rhabdomyolysis associated with cerivastatin therapy","volume":"161","author":"Simpson","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.amjmed.2012.08.007","article-title":"Alternate-day dosing with statins","volume":"126","author":"Marcus","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0105","doi-asserted-by":"crossref","first-page":"11230","DOI":"10.1016\/S0021-9258(18)82115-9","article-title":"Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme a reductase","volume":"268","author":"Parker","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.03.002_bib0110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0006-291X(78)90602-2","article-title":"Lack of correlation between the rate of cholesterol biosynthesis and the activity of 3-hydroxy-3-methylgutaryl coenzyme a reductase in rats and in fibroblasts treated with ML-236b","volume":"82","author":"Bensch","year":"1978","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2014.03.002_bib0115","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1161\/CIRCULATIONAHA.113.004243","article-title":"C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy","volume":"128","author":"Puri","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.03.002_bib0120","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1194\/jlr.M200440-JLR200","article-title":"A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers","volume":"44","author":"Hudgins","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0125","doi-asserted-by":"crossref","first-page":"e1003058","DOI":"10.1371\/journal.pgen.1003058","article-title":"Rhoa is a modulator of the cholesterol-lowering effects of statin","volume":"8","author":"Medina","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0130","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1074\/jbc.271.14.7916","article-title":"Regulation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo","volume":"271","author":"Meigs","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2014.03.002_bib0135","first-page":"I135","article-title":"Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein b","volume":"9","author":"Vega","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0140","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1194\/jlr.M700067-JLR200","article-title":"Effects of different doses of atorvastatin on human apolipoprotein b-100, b-48, and a-i metabolism","volume":"48","author":"Lamon-Fava","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2007.03.004","article-title":"Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome","volume":"197","author":"Ooi","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0150","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0022-2275(20)30112-7","article-title":"Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test","volume":"43","author":"Chan","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.metabol.2007.09.008","article-title":"Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia","volume":"57","author":"Hogue","year":"2008","journal-title":"Metabolism: Clin Exp"},{"key":"10.1016\/j.phrs.2014.03.002_bib0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0165","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0175","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.12.043","article-title":"Plasma pcsk9 levels and clinical outcomes in the tnt (treating to new targets) trial: a nested case\u2013control study","volume":"59","author":"Huijgen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0021-9150(03)00106-0","article-title":"Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high ldl cholesterol in a 4s subgroup","volume":"168","author":"Miettinen","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0185","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.numecd.2011.05.005","article-title":"The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption","volume":"21","author":"Miettinen","year":"2011","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0190","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-8703(03)00440-X","article-title":"Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the comparative hdl efficacy and safety study (CHESS)","volume":"146","author":"Ballantyne","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.phrs.2014.03.002_bib0195","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1476-5381.2011.01429.x","article-title":"Rosuvastatin does not affect human apolipoprotein a-i expression in genetically modified mice: a clue to the disputed effect of statins on hdl","volume":"164","author":"Marchesi","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2007.08.001","article-title":"Atorvastatin increases hdl cholesterol by reducing cetp expression in cholesterol-fed apoe*3-leiden. CEPT mice","volume":"197","author":"de Haan","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853890.2011.582135","article-title":"Clinical response to statins: mechanism(s) of variable activity and adverse effects","volume":"44","author":"Sirtori","year":"2012","journal-title":"Ann Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0215","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjp.0703920","article-title":"HMG-CoA reductase inhibitors and p-glycoprotein modulation","volume":"132","author":"Bogman","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0220","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of abcb1, cyp3a4, and cyp3a5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0225","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/humu.1206","article-title":"Mutations in ATP-cassette binding proteins g5 (abcg5) and g8 (abcg8) causing sitosterolemia","volume":"18","author":"Hubacek","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.phrs.2014.03.002_bib0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"Abcg2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0235","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"Slco1b1 variants and statin-induced myopathy \u2013 a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0240","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"Slco1b1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.002_bib0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"Degorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0250","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature12508","article-title":"A statin-dependent qtl for gatm expression is associated with statin-induced myopathy","volume":"502","author":"Mangravite","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2014.03.002_bib0255","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1476-5381.2010.01196.x","article-title":"Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing enos uncoupling","volume":"164","author":"Forstermann","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0260","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.110.002451","article-title":"Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies","volume":"123","author":"Patti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.03.002_bib0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/cvr\/cvp375","article-title":"Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability","volume":"86","author":"Massaro","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/07853890008998823","article-title":"Non-lipid-related effects of statins","volume":"32","author":"Bellosta","year":"2000","journal-title":"Ann Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0275","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(05)66196-X","article-title":"Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin","volume":"348","author":"Corsini","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0280","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.ATV.0000012802.69414.A8","article-title":"Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering","volume":"22","author":"Baetta","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0285","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"Nlrp3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2014.03.002_bib0290","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/01.CIR.0000029743.68247.31","article-title":"Simvastatin lowers c-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction","volume":"106","author":"Plenge","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2014.03.002_bib0295","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0300","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1902\/jop.2009.090429","article-title":"Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial","volume":"81","author":"Pradeep","year":"2010","journal-title":"J Periodontol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0305","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jacc.2013.08.1627","article-title":"High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins","volume":"62","author":"Subramanian","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0310","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkm496","article-title":"Unexpected antimicrobial effect of statins","volume":"61","author":"Jerwood","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.phrs.2014.03.002_bib0315","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-0711-11-13","article-title":"Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin","volume":"11","author":"Masadeh","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.phrs.2014.03.002_bib0320","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1111\/j.1439-0507.2010.01957.x","article-title":"Case\u2013control study of statin prevention of mould infections","volume":"54","author":"Thompson","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.phrs.2014.03.002_bib0325","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data \u2013 2005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0330","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0335","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2008.06.068","article-title":"Statins are safe for the treatment of hypercholesterolemia in patients with chronic liver disease","volume":"135","author":"Alqahtani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2014.03.002_bib0340","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0345","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2007.11.003","article-title":"Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization","volume":"198","author":"Naples","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0350","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2014.03.002_bib0355","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/jama.1988.03410020105038","article-title":"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients","volume":"260","author":"Corpier","year":"1988","journal-title":"JAMA: J Am Med Assoc"},{"key":"10.1016\/j.phrs.2014.03.002_bib0360","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0365","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0370","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ: Can Med Assoc J"},{"key":"10.1016\/j.phrs.2014.03.002_bib0375","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/hrt.2010.199034","article-title":"Individualising the risks of statins in men and women in England and Wales: population-based cohort study","volume":"96","author":"Hippisley-Cox","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2014.03.002_bib0380","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0706917","article-title":"Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study","volume":"149","author":"Pierno","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0385","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0390","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11883-010-0134-3","article-title":"Coenzyme Q(10) and statin myalgia: what is the evidence","volume":"12","author":"Mas","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.phrs.2014.03.002_bib0395","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2014.03.002_bib0400","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jcp.21810","article-title":"3-Hydroxy 3-methylglutaryl coenzyme a reductase increase is essential for rat muscle differentiation","volume":"220","author":"Martini","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0405","doi-asserted-by":"crossref","first-page":"885","DOI":"10.7326\/0003-4819-150-12-200906160-00014","article-title":"Balancing randomized trials with anecdote","volume":"150","author":"Phillips","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0410","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.phrs.2014.03.002_bib0415","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1097\/01.ASN.0000143720.71748.79","article-title":"Statin induced proteinuria: renal injury or renoprotection?","volume":"15","author":"Agarwal","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0420","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl-coa reductase reduce receptor-mediated endocytosis in opossum kidney cells","volume":"15","author":"Sidaway","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0425","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1053\/ajkd.2003.50140","article-title":"A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease","volume":"41","author":"Bianchi","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0430","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14740338.4.3.389","article-title":"Implications of statin adverse effects in the elderly","volume":"4","author":"Golomb","year":"2005","journal-title":"Expert Opin Drug Safe"},{"key":"10.1016\/j.phrs.2014.03.002_bib0435","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1592\/phco.23.15.1663.31953","article-title":"Cognitive impairment associated with atorvastatin and simvastatin","volume":"23","author":"King","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2014.03.002_bib0440","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1592\/phco.27.2.183","article-title":"Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial","volume":"27","author":"Summers","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2014.03.002_bib0445","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.03.002_bib0450","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneurol.2011.242","article-title":"Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations","volume":"68","author":"Shepardson","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.phrs.2014.03.002_bib0455","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.atherosclerosis.2013.07.009","article-title":"Long-term use of statins reduces the risk of hospitalization for dementia","volume":"230","author":"Corrao","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2014.03.002_bib0460","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1194\/jlr.M200002-JLR200","article-title":"Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in chbb: Thom rats","volume":"44","author":"Cenedella","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.phrs.2014.03.002_bib0465","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2013.4575","article-title":"Association of statin use with cataracts: a propensity score-matched analysis","author":"Leuschen","year":"2013","journal-title":"JAMA Ophthalmol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T16:09:57Z","timestamp":1648656597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":93,"alternative-id":["S1043661814000255"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.03.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacology of statins","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}